The O'Mara Law Firm Files Class Action Suit Against Spectrum Pharmaceuticals, Inc. and Reminds Investors of Lead Plaintiff Deadline

RENO, Nev., April 18, 2013 (GLOBE NEWSWIRE) -- The O'Mara Law Firm announces that it commenced a securities class action lawsuit in the United States District Court for the District of Nevada on behalf of purchasers of Spectrum Pharmaceuticals, Inc. ("Spectrum") (Nasdaq:SPPI) common stock during the period between August 8, 2012 and March 12, 2013, inclusive (the "Class Period").

The complaint charges Spectrum and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Spectrum is a biotechnology company with integrated commercial and drug development operations with a focus on hematology and oncology. In the United States, it markets two oncology drugs, FUSILEV® and ZEVALIV®.

FUSILEV is a folate analog used for the treatment of patients with advanced metastatic cancer. The key competitive formulation to FUSILEV was a generic drug, leucovorin. In 2008 and 2009, leucovorin supplies declined as one manufacturer reported low stockpiles due to increased demand and another stopped production due to expansion of its facility. These shortages of leucovorin represented a huge opportunity for Spectrum, as it was able to increase its sales of FUSILEV.

The complaint alleges that throughout the Class Period, defendants violated the federal securities laws by disseminating false and misleading statements to the investing public in connection with FUSILEV, continually dismissing concerns that sales of FUSILEV would be adversely affected by increased supplies of leucovorin and concealing the impact that the increased availability of leucovorin would have on FUSILEV sales. As a result of defendants' false statements, Spectrum's stock traded at artificially inflated prices during the Class Period, reaching a high of $13.05 per share on September 18, 2012.

On March 12, 2013, after the market closed, Spectrum issued a press release providing its full-year revenue outlook. The Company reported that sales of FUSILEV would be dropping significantly due to anticipated changes in ordering patterns for FUSILEV, which were due in part to the recent stabilization of the folate analog market. Additionally, the Company forecast full-year 2013 revenues in the range of $160 to $180 million, much lower than analysts' revenue expectations of $297.33 million for 2013. On this news, Spectrum's stock plummeted $4.64 per share to close at $7.79 per share on March 13, 2013, a one-day decline of 37% on volume of 22.5 million shares.

According to the complaint, the true facts, which were known by the defendants but concealed from the investing public during the Class Period, were as follows: (a) once the availability of leucovorin increased, Spectrum's sales of FUSILEV would plummet; (b) the purported advantages of FUSILEV over leucovorin would not be sufficient for clinics and hospitals to continue to opt for the more expensive FUSILEV once leucovorin was available in larger quantities; and (c) based upon the above, defendants lacked a reasonable basis for their positive statements about the Company and its revenue and earnings during the Class Period.

Plaintiffs seek to recover damages on behalf of all purchasers of Spectrum common stock during the Class Period (the "Class").

If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. If you wish to join this litigation or discuss your rights or interests, or if you would like a copy of the complaint, please contact plaintiffs' counsel, David O'Mara of The O'Mara Law Firm at 775-323-1321, or via e-mail at

The O'Mara Law Firm is a full-service law firm located in Reno, Nevada, serving a wide range of clients in both state and federal courts. With experience in areas such as complex commercial and civil litigation, the O'Mara Law Firm prosecutes securities class action litigation and actions involving financial fraud.

Attorney advertising. Prior results do not guarantee a similar outcome. Please visit for more information.

CONTACT: The O'Mara Law Firm David O'Mara 775-323-1321 david@omaralaw.netSource:The O'Mara Law Firm, P.C.